# US 2026/0098102 A1 · ANTI-SIRPalpha ANTIBODY

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098102 A1
- Document ID: US20260098102A1
- Status: Published application
- Kind: A1
- Application number: 19/374,973
- Filed: 2025-10-30
- Published: 2026-04-09
- Earliest claimed: 2018-07-10
- Assignees: National University Corporation Kobe University; Daiichi Sankyo Company, Limited
- Applicants: National University Corporation Kobe University; Daiichi Sankyo Company, Limited
- Inventors: Takashi MATOZAKI; Mayumi SUE; Kensuke NAKAMURA; Chigusa YOSHIMURA
- Web page: https://patentgrep.com/patent/US20260098102A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2887: {against CD20}
- C07K 16/32: against translation products of oncogenes
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47.

## Claims

### Claim 1

An antibody which comprises
(a) a light chain CDRL1 consisting of an amino acid sequence set forth in SEQ ID NO: 1;
(b) a light chain CDRL2 consisting of an amino acid sequence set forth in SEQ ID NO: 2;
(c) a light chain CDRL3 consisting of an amino acid sequence set forth in SEQ ID NO: 3;
(d) a heavy chain CDRH1 consisting of an amino acid sequence set forth in SEQ ID NO: 4;
(e) a heavy chain CDRH2 consisting of an amino acid sequence set forth in SEQ ID NO: 5; and
(f) a heavy chain CDRH3 consisting of an amino acid sequence set forth in SEQ ID NO: 6, and
which is any of the following (1) to (8):
(1) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of: a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO: 41; and a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO: 37;
(2) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of: a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO: 41; and a light chain comprising a light chain variable region consisting of an amino acid sequence having at least 95% sequence identity with amino acid residues 21 to 127 in SEQ ID NO: 37;
(3) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of: a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO: 41; and a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO: 39;
(4) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of: a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO: 41; and a light chain comprising a light chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO: 39;
(5) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of: a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO: 43; and a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO: 35;
(6) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of: a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO: 43; and a light chain comprising a light chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO: 35;
(7) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of: a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO: 43; and a light chain comprising a light chain variable region consisting of an amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO: 37; and
(8) an antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47, the antibody consisting of: a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 20 to 139 in SEQ ID NO: 43; and a light chain comprising a light chain variable region consisting of an amino acid sequence having at least 95% sequence identity with the amino acid sequence consisting of amino acid residues 21 to 127 in SEQ ID NO: 37.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the ADCC and/or ADCP activity is reduced.

### Claim 3 (depends on 1)

The antibody of claim 1, which enhances a phagocytic activity of a macrophage.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein a lysine residue at the carboxyl terminus of the heavy chain is deleted.

### Claim 5 (depends on 1)

An antigen-binding fragment of the antibody according to claim 1.

### Claim 6 (depends on 5)

The antigen-binding fragment of the antibody of claim 5, wherein the antigen-binding fragment is selected from the group consisting of Fab, F(ab′)2, Fab′, and scFv.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 or an antigen-binding fragment of the antibody according to claim 1 as an active ingredient.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is an anti-tumor agent.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, further comprising an immune checkpoint inhibitor and/or an antibody drug that specifically responds to a cancer antigen to have the ADCC and/or ADCP activity as an active ingredient of the anti-tumor agent.

### Claim 10 (depends on 1)

A pharmaceutical composition which is an anti-tumor agent used in combination with an immune checkpoint inhibitor and/or an antibody drug that specifically responds to a cancer antigen to have the ADCC and/or ADCP activity, wherein the pharmaceutical composition comprises the antibody of claim 1 or an antigen-binding fragment of the antibody of claim 1 as an active ingredient.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the immune checkpoint inhibitor is an inhibitor of binding of PD-L1 to PD-1 or a CTLA4 inhibitor.

### Claim 12 (depends on 9)

The pharmaceutical composition of claim 9, wherein the antibody drug that specifically responds to a cancer antigen to have the ADCC and/or ADCP activity is selected from the group consisting of an anti-CD20 antibody, an anti-HER2 antibody, and an anti-EGFR antibody.

### Claim 13 (depends on 8)

The pharmaceutical composition of claim 8, wherein the tumor is one type or two or more types of tumors selected from the group consisting of carcinoma, sarcoma, lymphoma, leukemia, myeloma, germinoma, brain tumor, carcinoid, neuroblastoma, retinoblastoma, and nephroblastoma.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the tumor is one type or two or more types of tumors selected from the group consisting of kidney cancer, melanoma, squamous cell cancer, basal cell cancer, conjunctival cancer, oral cancer, laryngeal cancer, pharyngeal cancer, thyroid cancer, lung cancer, breast cancer, esophageal cancer, gastric cancer, duodenal cancer, small intestinal cancer, colon cancer, rectal cancer, appendix cancer, anal cancer, liver cancer, gallbladder cancer, biliary cancer, pancreatic cancer, adrenal cancer, bladder cancer, prostate cancer, uterine cancer, vaginal cancer, liposarcoma, angiosarcoma, chondrosarcoma, rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, malignant peripheral neurilemmoma, retroperitoneal sarcoma, synoviosarcoma, uterine sarcoma, gastrointestinal stromal tumor, leiomyosarcoma, epithelioid sarcoma, B-cell lymphoma, NK/T-cell lymphoma, Hodgkin's lymphoma, myeloid leukemia, lymphatic leukemia, myeloproliferative disease, myelodysplastic syndrome, multiple myeloma, testicular cancer, ovarian cancer, neuroglioma, and meningioma.

### Claim 15 (depends on 1)

A polynucleotide consisting of nucleotide sequences encoding amino acid sequences of a heavy chain and a light chain of the antibody of claim 1 or amino acid sequences of an antigen-binding fragment of the antibody of claim 1.

### Claim 16 (depends on 15)

A vector comprising the polynucleotide according to claim 15.

### Claim 17 (depends on 15)

A host cell comprising the polynucleotide according to claim 15 or a vector comprising the polynucleotide according to claim 15.

### Claim 18 (depends on 1)

A method for producing the antibody of claim 1, comprising culturing a host cell comprising a polynucleotide consisting of nucleotide sequences encoding amino acid sequences of a heavy chain and a light chain of the antibody of claim 1 or a vector comprising a polynucleotide consisting of nucleotide sequences encoding amino acid sequences of a heavy chain and a light chain of the antibody of claim 1.

### Claim 19 (depends on 18)

An antibody produced by the method according to claim 18.
